SOLICITATION NOTICE
A -- Development of a Biomarker for Skin Cancer Risk
- Notice Date
- 12/30/2002
- Notice Type
- Solicitation Notice
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-30017-NG
- Archive Date
- 1/29/2003
- Point of Contact
- Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Caren Rasmussen, Lead Contract Specialist, Phone (301) 402-4509, Fax (301) 402-4513,
- E-Mail Address
-
holdcram@exchange.nih.gov, cr214i@nih.gov
- Description
- The National Institutes of Health (NIH), National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics, Radiation Epidemiology Branch, intends to procure on a sole-source basis with Timothy J. Jorgensen, Ph.D., Associate Professor, Department of Radiation Medicine, Lombardi Cancer Center, 3970 Reservoir Road, N.W., Washington, D.C.; services in support of the Development of a Biomarker for Skin Cancer Risk. The North American Industry Classification System Code is 621511 and the business size standard is $11.5M. The purpose of this project is to support the pilot work to develop a biomarker for individual tumor susceptibility. This will be used in epidemiologic studies of skin cancer in relation to exposure to ionizing radiation and ultraviolet radiation. The Patched gene (PTCH) is a developmental gene, first identified in Drosophila, with widespread conservation among a variety of species, including humans. During Stage I, first 6 months of study, the contractor shall prepare and insert a human PTCH-GFP construct similar to mouse PTCH-LacZ construct, along with a CMV-HcRed construct, into an expression vector system. HcRed (BD Biosciences Clontech) is a far-red fluorescent protein. The protein's coding sequence has been human codon optimized to improve its expression in mammalian cells. Because it fluoresces in the far-red region of the spectrum, HcRed provides a very high signal-to-noise ration, virtually no cellular autofluorescence, and complete separation from the GFP signal. During Stage II, months 7-12 of contract (depending on the results of the first 6 months, the contractor shall: The reporter system will be tested in a panel of normal and tumor skin cell lines, since skin (basal) cells are the primary target tissue of interest. Neither normal basal cell lines nor BCC tumor cell lines are readily available. The contractor will also evaluate PTCH reporter vector in EBV-transformed lymphoblasts, since these are often the only viable cells that are available from study populations. A comparison will be made from the results from skin cell lines with those from lymphoblasts, to determine how effective lymphoblasts are as a surrogate cell type for predicting PTCH functionality in skin. Dr. Jorgensen's laboratory is the only known source to the Government as the particular type of biomarker being developed which was conceived by him, and thus is original and unable to be duplicated. The contractor's radiation biology laboratory has a long standing interest in molecular mechanisms of radiation responses, and particularly in the proteins and genes that protect cells from the harmful effects of ionizing radiation. The laboratory has focused exclusively on human cell systems and has studied a number of molecular markers thought to be important to radiation resistance and protection against radiation-induced cancer, including ATM, p53, and PTCH. They also have experience in developing DNA repair assays that can be used on human leukocytes and in the use of flow cytometry for assay protection. The contractor has expertise in radiation biology and oncology, demonstrated experience in identifying a number of molecular markers related to host susceptibility, and skills in developing DNA repair assays with added capability of using automated flow cytometry. This is not a request for competitive quotations. However, if any interested party believes it can perform the above requirement, it may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow NCI to determine if it can meet the above minimum specifications described herein. Capability statements must be received in the Contracting Office by 1:00 PM EST (local Washington, D.C. time) on January 14, 2003. If you have any questions, please contact Malinda Holdcraft, Purchasing Agent via electronic mail at holdcram@exchange.nih.gov or by fax on (301) 402-4513. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. Faxed copies of capability statements will not be accepted. All interested parties are to submit one (1) original and two (2) copies to the following address: Malinda Holdcraft, Purchasing Agent, NIH/NCI/RCB, 6120 Executive Blvd., Room 6072, Rockville, Maryland 20852-7194.
- Place of Performance
- Address: NIH/NCI, 9000 Rockville Pike, Bethesda, MD
- Zip Code: 20892
- Country: USA
- Zip Code: 20892
- Record
- SN00232172-W 20030101/021230213202 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |